H Kirsche1, L Klimek. 1. Universitätsklinikum Münster, Klinik für Hals-Nasen-Ohrenheilkunde, Kardinal-von-Galen-Ring 10, 48149, Münster, Deutschland, hanspeter.kirsche@ukmuenster.de.
Abstract
BACKGROUND: A differential diagnosis of persistent chronic rhinosinusitis is ASA-intolerance syndrome (AIS), also known as Aspirin®‑exacerbated respiratory disease (AERD), Samter-Trias (Samter's disease, Morbus Widal). Particularly in cases of frequent recurrency of nasal polyps in combination with bronchial asthma and hypersensitivity reactions to acetylsalicylic acid (ASA) and other nonsteroidal anti-inflammatory drugs (NSAR) can often be referred to an underlying AIS. The pathogenesis of this syndrome is attributed to a misallocation of the arachidonic acid metabolism, resulting in an increased leukotriene production. METHODS: The diagnosis may be difficult in the early stages of the disease with incomplete triad of symptoms. RESULTS: Therapy may consist of paranasal sinuses surgery, drug therapy and adaptive deactivation as the only causal treatment option for patients with AIS. CONCLUSION: For adaptive desactivation, positive effects were actually shown even in patients with long-term recurrent or persistent complaints of chronic rhinosinusitis.
BACKGROUND: A differential diagnosis of persistent chronic rhinosinusitis is ASA-intolerance syndrome (AIS), also known as Aspirin®‑exacerbated respiratory disease (AERD), Samter-Trias (Samter's disease, Morbus Widal). Particularly in cases of frequent recurrency of nasal polyps in combination with bronchial asthma and hypersensitivity reactions to acetylsalicylic acid (ASA) and other nonsteroidal anti-inflammatory drugs (NSAR) can often be referred to an underlying AIS. The pathogenesis of this syndrome is attributed to a misallocation of the arachidonic acid metabolism, resulting in an increased leukotriene production. METHODS: The diagnosis may be difficult in the early stages of the disease with incomplete triad of symptoms. RESULTS: Therapy may consist of paranasal sinuses surgery, drug therapy and adaptive deactivation as the only causal treatment option for patients with AIS. CONCLUSION: For adaptive desactivation, positive effects were actually shown even in patients with long-term recurrent or persistent complaints of chronic rhinosinusitis.
Authors: B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; K Hörmann Journal: HNO Date: 2007-10 Impact factor: 1.284
Authors: L Klimek; S Becker; R Buhl; A M Chaker; T Huppertz; T K Hoffmann; S Dazert; T Deitmer; U Förster-Ruhrmann; H Olze; J Hagemann; S K Plontke; H Wrede; W Schlenter; H J Welkoborsky; B Wollenberg; A G Beule; C Rudack; S Strieth; R Mösges; C Bachert; T Stöver; C Matthias; A Dietz Journal: Laryngorhinootologie Date: 2020-05-08 Impact factor: 1.057
Authors: Ludger Klimek; Ulrike Förster-Ruhrmann; Achim G Beule; Adam M Chaker; Jan Hagemann; Felix Klimek; Ingrid Casper; Tilman Huppertz; Thomas K Hoffmann; Stefan Dazert; Thomas Deitmer; Heidi Olze; Sebastian Strieth; Holger Wrede; Wolfgang W Schlenter; Hans-Jürgen Welkoborsky; Barbara Wollenberg; Christoph Bergmann; Mandy Cuevas; Caroline Beutner; Moritz Gröger; Sven Becker Journal: Allergo J Date: 2022-09-05